#Uterine Fibroids Drug Market Industry

[neha24blog]

Uterine Fibroid Treatment Drugs Market Segment Analysis By Drug Class, Type, End-User, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 17 Aug 2023: The Report Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (GnRH Agonists, GnRH Antagonists), By Type (Submucosal Fibroids, Intramural Fibroids), By End-user, And Segment Forecasts, 2023 – 2030 The global uterine fibroid treatment drugs market size is expected to reach USD 3.91 billion by 2030, expanding at a CAGR of 10.2%…

[mariacallous]

On Tuesday, the Supreme Court of the United States will hear oral arguments in a challenge to abortion pill access across the country, including in states where abortion is legal. The stakes for abortion rights are sky-high, and the case is the most consequential battle over reproductive health care access since Roe v. Wade was overturned in 2022.

At the center of this fight is mifepristone, a pill that blocks a hormone needed for pregnancy. The drug has been approved by the US Food and Drug Administration for more than two decades, and it’s used to treat some patients with Cushing’s syndrome, as well as endometriosis and uterine fibroids. But its primary use is the one contested now—mifepristone is the first of two pills taken in the first 10 weeks of pregnancy for a standard medication abortion, along with the drug misoprostol.

If the justices side with the antiabortion activists seeking to limit access to mifepristone, it could upend nationwide access to the most common form of abortion care. A ruling that invalidates mifepristone’s approval would open the door for any judge to reverse the FDA approval of any drug, especially ones sometimes seen as controversial, such as HIV drugs and hormonal birth control. It could also have a chilling effect on the development of new drugs, making companies wary of investing research into medicines that could later be pulled from the market.

Pills are now the leading abortion method in the US, and their popularity has spiked in recent years. More than six in 10 abortions in 2023 were carried out via medication, according to new data from the Guttmacher Institute. Since rules around telehealth were relaxed during the Covid-19 pandemic, many patients seeking medication abortions have relied on virtual clinics, which send abortion pills by mail. And it keeps getting more popular: Hey Jane, a prominent telemedicine provider, saw demand increase 73 percent from 2022 to 2023. It recorded another 28 percent spike comparing data from January 2023 to January 2024.

“Telemedicine abortion is too effective to not be in the targets of antiabortion folks,” says Julie F. Kay, a longtime reproductive rights lawyer and director of the advocacy group Abortion Coalition for Telemedicine.

Tomorrow’s argument comes after a long, tangled series of legal disputes in lower courts. The Supreme Court will be hearing two cases consolidated together, including FDA v. Alliance for Hippocratic Medicine, in which a coalition of antiabortion activists filed a suit challenging the FDA’s approval of mifepristone, asking for it to be removed from the market. The Alliance for Hippocratic Medicine is represented by the Alliance Defending Freedom, a right-wing Christian law firm that often takes politically charged cases.

Despite decades of scientific consensus on the drug’s safety record, the Alliance for Hippocratic Medicine has alleged that mifepristone is dangerous to women and leads to emergency room visits. A 2021 study cited by the plaintiffs to back up their claims was retracted in February after an independent review found that its authors came to inaccurate conclusions.

In April 2023, the Trump-appointed judge Matthew Kacsmaryk of the Northern District of Texas issued a preliminary ruling on the FDA case invalidating the agency’s approval of mifepristone. The ruling sent shock waves far beyond the reproductive-rights world, as it had major implications for the entire pharmaceutical industry, as well as the FDA itself; the ruling suggested that the courts could revoke a drug’s approval even after decades on the market.

The US 5th Circuit Court of Appeals narrowed Kacsmaryk’s decision a week later, allowing the drug to remain on the market, but undid FDA decisions in recent years that made mifepristone easier to prescribe and obtain. That decision limited the time frame in which it can be taken to the first seven weeks of pregnancy and put telemedicine access, as well as access to the generic version of the drug in jeopardy.

Following the 5th Circuit ruling, the FDA and Danco Laboratories sought emergency relief from the Supreme Court, asking the justices to preserve access until it could hear the case. In its legal filing, Danco aptly described the situation as “regulatory chaos.”

SCOTUS issued a temporary stay, maintaining the status quo; the court ultimately decided to take up the case in December 2023.

As all this was unfolding, pro-abortion-rights states across the country were passing what are known as shield laws, which protect medical practitioners who offer abortion care to pregnant patients in states where abortion is banned. This has allowed some providers, including the longtime medication-abortion-advocacy group Aid Access, to mail abortion pills to people who requested them in states like Louisiana and Arkansas.

Though the oral arguments before the Supreme Court begin on Tuesday, it will likely be months before a ruling. Court watchers suspect a decision may be handed down in June. With the US presidential election in the fall, the ruling may become a major campaign issue, especially as abortion access helped galvanize voters in the 2022 midterms.

If the Supreme Court agrees with the plaintiffs that mifepristone should be taken off the market, some in the pharmaceutical industry worry that it will undermine the authority of the FDA, the agency tasked with reviewing and approving drugs based on their safety and efficacy.

“This case isn't about mifepristone,” says Elizabeth Jeffords, CEO of Iolyx Therapeutics, a company developing drugs for immune and eye diseases. Jeffords is a signatory on an amicus brief filed in April 2023 that brought together 350 pharmaceutical companies, executives, and investors to challenge the Texas district court’s ruling.

“This case could have easily been about minoxidil for hair loss. It could have been about Mylotarg for cancer. It could have been about measles vaccines,” Jeffords says. “This is about whether or not the FDA is allowed to be the scientific arbiter of what is good and safe for patients.”

Greer Donley, an associate professor of law at the University of Pittsburgh and an expert on abortion on the law, doesn’t think it’s likely that the court will revoke mifepristone’s approval entirely. Instead, she sees two possible outcomes. The Supreme Court could dismiss the case or could undo the FDA’s decision in 2023 to permanently remove the in-person dispensing requirement and allow abortion by telehealth. “This would be an even more narrow decision than what the 5th Circuit did, but it would still be pretty devastating to abortion access,” she says.

The Supreme Court could also decide that the plaintiffs lack a right to bring the case to court, says David Cohen, a professor of law at Drexel University whose expertise is in constitutional law and gender issues. “This case could get kicked out on standing, meaning that the plaintiffs aren't the right people to bring this case,” he says. “If most of the questions are about standing, that will give you a sense that that's what the justices are concerned about.”

As the current Supreme Court is considered virulently antiabortion, reproductive-health-care workers are already preparing for the worst. Some telehealth providers have already floated a backup plan: offering misoprostol-only medication abortions. This is less than ideal, as the combination of pills is the current standard of care and offers the best results; misoprostol on its own can cause additional cramping and nausea. For some providers who may have to choose between misoprostol-only or nothing, it’s better than nothing.

Abortion-rights activists have no plans to give up on telehealth abortions, regardless of the outcome of this particular case. “Let us be clear, Hey Jane will not stop delivering telemedicine abortion care, regardless of the outcome of this case,” says Hey Jane’s CEO and cofounder, Kiki Freedman.

“They’re not going to stuff the genie back in the bottle,” Kay says.

[industryforecastnews]

Women’s Health Market Size, Share & Trends Analysis Report, 2030

Women's Health Market Growth & Trends

The global women’s health market size is expected to reach USD 67.07 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women’s health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women’s health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/womens-health-market

Women's Health Market Report Highlights

The contraceptives segment held the highest market share of more than 35.25% of the global revenue in 2023 due to increased awareness about family planning and rapid technological advancements in contraception

The University of California Bixby Center released a reimbursement guide to help health providers offer women a full range of contraceptives

The endometriosis segment is expected to witness significant growth over the forecast period due to the launch of products, such as Relugoliz and the impending launch of Linzagolix for the treatment of women with uterine fibroids

Based on age, the 50 years and above segment is expected to register the fastest growth rate of 6.7% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe

According to the International Menopause Society, globally, women aged between 45 and 55 years typically experience menopause, with the average age of onset at 51.5 years

Women's Health Market Segmentation

Grand View Research has segmented the global Women's Health market on the basis age, application, drugs, and region:

Women's Health Application Outlook (Revenue, USD Million, 2018 - 2030)

Hormonal Infertility

Contraceptives

Postmenopausal Osteoporosis

Endometriosis & Uterine Fibroids

Menopause

Polycystic Ovary Syndrome (PCOS)

Women's Health Drug Outlook (Revenue, USD Million, 2018 - 2030)

ACTONEL

YAZ,Yasmin,Yasminelle

FORTEO

Minastrin 24 Fe

Mirena

NuvaRing

ORTHO TRI-CY LO

Premarin

Prolia

Reclast/Aclasta

XGEVA

Zometa

Others

Women's Health Age Outlook (Revenue, USD Million, 2018 - 2030)

50 years and above

Postmenopausal Osteoporosis

Endometriosis & Uterine Fibroids

Menopause

Others

Others

Women's Health Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

S.

Canada

Europe

Germany

K.

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

India

Japan

Australia

South Korea

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of Women’s Health Market

AbbVie, Inc.

Bayer AG

Merck & Co., Inc.

Pfizer, Inc.

Teva Pharmaceutical Industries Ltd.

Agile Therapeutics

Amgen, Inc.

Apothecus Pharmaceutical Corp.

Blairex Laboratories, Inc.

Ferring B.V.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/womens-health-market

[mrfr-blogs]

Market Outlook for Leuprolide Acetate Market Services

Market Overview –

The Leuprolide Acetate Market focuses on the production, distribution, and use of the medication Leuprolide Acetate, a synthetic hormone analogue used in the treatment of various medical conditions. Leuprolide Acetate is primarily prescribed for managing hormone-related conditions such as prostate cancer, breast cancer, endometriosis, and uterine fibroids.

One significant factor driving the growth of the Leuprolide Acetate Market is the increasing prevalence of hormone-dependent disorders and cancers. Prostate cancer and breast cancer are among the most common cancers worldwide, and Leuprolide Acetate is often prescribed as part of hormone therapy to reduce tumor growth and manage symptoms.

Additionally, Leuprolide Acetate is used in the treatment of gynecological conditions such as endometriosis and uterine fibroids, which affect millions of women globally. The medication helps alleviate symptoms such as pelvic pain, heavy menstrual bleeding, and infertility by suppressing estrogen production and inducing a temporary menopausal state.

The market for Leuprolide Acetate includes various formulations such as injectable depot formulations, subcutaneous implants, and nasal sprays, providing healthcare providers with options to tailor treatment regimens to individual patient needs. Additionally, generic versions of Leuprolide Acetate are available, offering cost-effective alternatives to branded formulations.

As healthcare systems strive to improve access to affordable and effective treatments for hormone-related conditions and cancers, the demand for Leuprolide Acetate is expected to continue growing. Pharmaceutical companies that innovate in drug delivery technologies, dosage forms, and formulations will remain competitive in this dynamic market, driving further advancements and opportunities for patients and healthcare providers alike.

The Leuprolide Acetate Market, also known as leuprolide injection market, is witnessing steady growth due to its widespread use in treating various conditions like prostate cancer, endometriosis, and uterine fibroids. Rising awareness about its efficacy and increasing prevalence of these conditions are driving market expansion.

The leuprolide acetate market is expected to reach USD 2,400 million by 2030, growing at a 10.50% CAGR during the forecast period 2022-2030.

Market Segmentation –

Globally, the market is segmented based on application, mode of administration, and end-users.

According to the application, the leuprolide acetate business is classed as prostate cancer, uterine fibroid in females, precocious, and many others.

According to the administration, the industry is separated into intramuscular and subcutaneous. The industry is divided into end-user segments such as hospitals, medical facilities, clinics, and others.

The market is segmented by end-users into medicals, clinics, research fields, and some academic institutions. According to the geographical study, the market is divided into several regions, including Europe, Asia, North America, and the rest of the globe.

Some companies' technology focuses heavily on research activities. Adopting technology in line with new leuprolide acetate market trends provides valuable insights that aid in the growth and development of the organization. Furthermore, technology assisted market players in achieving an optimal position in the industry.

Regional Analysis –

The regional analysis of the Leuprolide Acetate market reveals varying dynamics across different parts of the world. North America dominates the market, attributed to the high prevalence of conditions like prostate cancer and endometriosis, coupled with advanced healthcare infrastructure and favorable reimbursement policies. In Europe, the market experiences steady growth driven by increasing awareness about treatment options and rising healthcare expenditure. The Asia-Pacific region showcases significant growth potential due to improving access to healthcare, growing aging population, and increasing investments in healthcare infrastructure. Emerging markets in Latin America and Africa are also witnessing gradual market expansion as awareness about hormonal disorders and cancer treatment options increases, and healthcare systems continue to develop.

Key Players –

Analysis of the Leuprolide Acetate market's driving and challenging factors aids in refining marketing strategies to achieve competitive advantage. Competitors in the Leuprolide Acetate Market include COLMAR Pharmaceuticals, Pfizer Inc. (USA), Varian Pharmed (Iran), Merck kGaA (Germany), Avent AG (Switzerland), Abbott (USA), Takeda Pharmaceuticals Company Ltd (Japan), Astellas Pharma (Japan), Sun Pharmaceuticals Industries Ltd (India), Sanofi (France), Livzon Pharma Group Co. Ltd (China), AbbVie Inc. (USA), Beijing Biota Pharmaceuticals Co. Ltd (China), Soho-Filming (China), among others. Market growth is concentrated, prompting vendors to employ both organic and inorganic growth strategies for global competition. Company profiles highlight sustainability in production units and the rising prospectus rate of leading competitors.

Related Reports –

US Melanoma

Middle East and Africa HIV Diagnosis & Treatment

Gastroparesis Treatment

Dental Infection Treatment

For more information visit at MarketResearchFuture

[marketsresearchdbmr]

Uterine Fibroids Drug Market Research Report with Outlook, Strategies, Challenges, Geography Trends

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[dbmrresearchreports]

Uterine Fibroids Drug Market Research, Agency, Business Opportunities with New Players

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[marketresearchanalysis]

Uterine Fibroids Drug Market in Global Industry: Demands, Insights, Research and Forecast 2020-2026

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[researchindustry]

Uterine Fibroids Drug Market Size, Business Revenue Forecast, Leading Competitors and Growth Trends 2026

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[marketnewsreport]

Uterine Fibroids Drug Market to Exhibit Impressive Growth during 2020-2026

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[peeterdbmr]

Uterine Fibroids Drug Market Research Report with Outlook, Strategies, Challenges, Geography Trends

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[newsresearch]

Uterine Fibroids Drug Market Research Report with Outlook, Strategies, Challenges, Geography Trends

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[researchupdates]

Explosive growth on Uterine Fibroids Drug Market 2021-2028: Global Companies like GSK, Roche, Pfizer, Sanofi, Teva, Amgen, Mylan, Sun Pharma

Overview of Global Uterine Fibroids Drug Market:

An international Uterine Fibroids Drug Market report covers a Market overview and the growth prospects of the Market. The current environment of the Healthcare industry and the key trends determining the Market are presented in the report. The Market report is a complete overview of the Market, covering various aspects like product definition, segmentation based on various parameters, and the prevailing vendor landscape. Insightful predictions for the coming few years have also been taken into consideration in this business research study. These predictions feature important inputs from leading industry experts and underline every statistical detail regarding the Market.

The winning Uterine Fibroids Drug report suggests that the Market is growing at a very fast pace and with the rise in technological innovation, competition and M&A activities in the business many local and regional vendors are offering specific application products for varied end-users. This report contains historic data, present Market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Global Uterine Fibroids Drug Market report includes all the company profiles of the top Market players and brands. Healthcare industry is anticipated to witness higher growth during the forecast period due to growing demand at the end user level.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market .

The Global Uterine Fibroids Drug Market is expected to gain market growth at a potential rate of 9.45% in the forecast period of 2021 to 2028.

According to the market report analysis, Uterine Fibroids are also known as leiomyoma or myomas, which can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus. A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

The most significant key factors driving the growth of the Global Uterine Fibroids Drug Market are increase in the prevalence of uterine fibroids, increase in the government awareness programs about the disease, rise in the awareness amongst people about the uterine fibroids and its treatment, rise in the availability of efficient and innovative therapies and the high purchasing power of women, continuous change in lifestyle mainly dietary pattern, and rise in the number of Women of Reproductive Age (WRA) across the globe.

Top Leading Key Manufacturers are: GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo International plc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V and IceCure Medical and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

In terms of the geographic analysis, North America dominates the uterine fibroids drug market due to rise in the number of patients suffering from uterine fibroid problem, rise in the availability of efficient and innovative therapies and the high purchasing power of women and continuous change in lifestyle mainly dietary pattern in this region. APAC is the expected region in terms of growth in uterine fibroids drug market due to increase in the awareness, increase in the favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region.

Access Complete Report Here: https://www.databridgemarketresearch.com/reports/global-uterine-fibroids-drug-market .

[blueweave01]

Global Women’s Healthcare Market Set to Register Moderate Growth: Expected to Reach USD 46,163.53 million in 2027

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global women’s healthcare market reached USD 33,182.02  million in 2020. The data estimated by the study further reveals that the market is projected to reach USD 46,163.53 million by 2027, growing at a CAGR of 4.9% during 2021-2027 (forecast period). The global women's healthcare market is expanding due to rising government measures to reduce population, an increase in the frequency of chronic illnesses among women worldwide, and a surge in demand for contraception to minimize unintended pregnancies. This has raised the demand for women's healthcare, favorably impacting the worldwide women's healthcare market.

The rise in women-specific health disorders is amplifying the global women’s healthcare market

According to a report published by the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million by 2050. According to the Society of Obstetricians and Gynecologists of Canada (SOGC), around 80% of women experience more than one menopausal symptom, such as disrupted sleep, mood fluctuations, and increased irritability. Also, the GLOBOCAN report for the year 2018 released by the International Agency for Research on Cancer (IARC) states that female breast cancer diagnosis totaled 2.1 million cases in 2018, accounting for an estimated 11.6% of all global cancer cases. As a result, the rapid rise in the number of women-specific health disorders is generating demand for the global women’s healthcare market.

Growing Prevalence of Polycystic Ovary Syndrome (PCOS) have contributed to the growth of the global women’s healthcare market

PCOS is a hormonal disorder prevalent in premenopausal women worldwide, causing reproductive, endocrine, and metabolic abnormalities. The surge in the number of cases of PCOS has significantly assisted in the growth of the global women’s healthcare market since it requires a strict medical regimen. Oral contraceptive combinations, particularly those containing progestins such as norgestimate, desogestrel, or drospirenone (due to their minimal androgenic effects), are among the most often used drugs for hirsutism in women with PCOS. Hormonal aberrations are common in women with PCOS (elevated androgen levels) leading to menstrual irregularities like oligomenorrhea, amenorrhea, and others, which causes dysfunctional uterine bleeding & infertility. Thus, the wide range of medications used for treating PCOS and the rise in instances of PCOS are contributing to the global women's healthcare market’s growth.

The Prolia drug sub-segment occupies the largest market share in the global women’s healthcare market

Based on drugs, the global women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Zometa, Reclast/Aclasta, Minastrin 24 Fe, FORTEO, Premarin, ACTONEL, and others. Prolia accounted for the largest market share in the global women’s healthcare market in 2020 and is further projected to record a strong CAGR during the forecast period (2021-2027). The drug acts as an effective medicine for curing osteoporosis in women. Since women are more prone to confront bone and calcium-related issues than men, the need for bone-related treatment becomes inevitable making the drug more essential for consumption. As a result, the drug has been driving the growth of the global women’s healthcare market.

The hospitals & clinics segment registered the largest share in the global women’s healthcare market’s end-user segment

Based on end-users, the global women’s healthcare market is segmented into hospitals & clinics, gynecology centers, research institutes, and others. The hospitals & clinics segment accounted for the largest share in the global women’s healthcare market and is expected to register a healthy CAGR during the forecast period.  People prefer visiting hospitals and gynaecology centers owing to the presence of specialized and highly qualified surgeons and physicians. The growing insurance and reimbursement policies driven by the government initiatives in various developed regions have been driving women to opt for treatments in hospitals.

The Global Women’s Healthcare Market: Regional Insights

Based on region, the global women’s healthcare market is divided into North America, Europe, the Asia-Pacific, Latin America, and the Middle East and Africa. In the year 2020, the North American region accounted for the greatest market share in the global women’s healthcare market. According to U.S. census demographics, the region has a growing female population over the age of 35, which indicates a rising demand for female healthcare. This will have a significant impact on the demand for treatment and drugs associated with women's healthcare in the region, as well as the global women's healthcare market.

COVID-19 Impact Analysis

The UN report on the impact of COVID-19 on women discovered that overburdened health facilities, as a result of COVID-19, are diverting resources away from services women require, such as pre- and post-natal healthcare and contraception. When it comes to accessing help, women confront unique challenges. According to the findings of a recent UN Women and UNFPA report, 'Impact of COVID-19 on Gender Equality and Women's Empowerment in East and Southern Africa', the pandemic has had far-reaching and diversified repercussions on women and girls in East and Southern Africa. Additionally, there has been an upsurge in the incidence of neonatal and maternal problems in COVID-19 positive pregnant mothers. It has resulted in an increased rate of miscarriage, preterm birth, pre-eclampsia, cesarean section, and perinatal death. These fatal complications have created the demand for an effective and accessible women's healthcare market for all of its users worldwide.

Some of the leading players in the global women’s healthcare market are Bayer AG, Allergan, Becton & Dickson, Elly Lilly, Merck & Co, Pfizer Inc., Amgen, Agile Therapeutics Inc., Ferring Pharmaceuticals Mylan N.V., and other prominent players. The prevalence of various women’s healthcare manufacturers around the world has paved the way for rising opportunities among the new entrants in the global women’s healthcare market owing to which the global women’s healthcare is fragmented in nature.

In May 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.

Don’t miss the business opportunity of the Global Women’s Healthcare market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global women’s healthcare market size & forecast. The report promises to provide recent technology trends of the global women’s healthcare market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the global women’s healthcare market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer all-inclusive market research reports by analysing both qualitative and quantitative data to boost up the performance of your business solutions. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

[researchindustry]

Uterine Fibroids Drug Market Set to Grow at Healthy CAGR forecast by 2026

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

·         By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)

·         By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)

·         By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)

·         By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)

·         By Treatment (Medication, Dietary Supplements and Surgery)

·         By Route of Administration (Oral, Intravenous and Others)

·         By End-Users (Hospitals, Homecare, Specialty Clinics and Others)

·         By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

·         Increasing prevalence of uterine fibroids is driving the market growth

·         Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver

·         Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

·         Side effects of treatment such as bleeding and infection during surgery can hamper the market growth

·         Low healthcare expenditure in developing regions also restricts the market growth

·         High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.

·         Limited treatment options for uterine fibroids are restricting the market growth.

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market

Reasons to Purchase this Report:

·         Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

·         The latest developments, market shares, and strategies that are employed by the major market players.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818   

Related Reports:

Opioids Drug Market

Monoamine Oxidase (MAO) Inhibitor Drugs Market

[blueweave]

Global Women’s Healthcare Market Set to Register Moderate Growth: Expected to Reach USD 46,163.53 million in 2027

 A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global women’s healthcare market reached USD 33,182.02  million in 2020. The data estimated by the study further reveals that the market is projected to reach USD 46,163.53 million by 2027, growing at a CAGR of 4.9% during 2021-2027 (forecast period). The global women's healthcare market is expanding due to rising government measures to reduce population, an increase in the frequency of chronic illnesses among women worldwide, and a surge in demand for contraception to minimize unintended pregnancies. This has raised the demand for women's healthcare, favorably impacting the worldwide women's healthcare market.

The rise in women-specific health disorders is amplifying the global women’s healthcare market

According to a report published by the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million by 2050. According to the Society of Obstetricians and Gynecologists of Canada (SOGC), around 80% of women experience more than one menopausal symptom, such as disrupted sleep, mood fluctuations, and increased irritability. Also, the GLOBOCAN report for the year 2018 released by the International Agency for Research on Cancer (IARC) states that female breast cancer diagnosis totaled 2.1 million cases in 2018, accounting for an estimated 11.6% of all global cancer cases. As a result, the rapid rise in the number of women-specific health disorders is generating demand for the global women’s healthcare market.

Growing Prevalence of Polycystic Ovary Syndrome (PCOS) have contributed to the growth of the global women’s healthcare market

PCOS is a hormonal disorder prevalent in premenopausal women worldwide, causing reproductive, endocrine, and metabolic abnormalities. The surge in the number of cases of PCOS has significantly assisted in the growth of the global women’s healthcare market since it requires a strict medical regimen. Oral contraceptive combinations, particularly those containing progestins such as norgestimate, desogestrel, or drospirenone (due to their minimal androgenic effects), are among the most often used drugs for hirsutism in women with PCOS. Hormonal aberrations are common in women with PCOS (elevated androgen levels) leading to menstrual irregularities like oligomenorrhea, amenorrhea, and others, which causes dysfunctional uterine bleeding & infertility. Thus, the wide range of medications used for treating PCOS and the rise in instances of PCOS are contributing to the global women's healthcare market’s growth.

Request to Download Free Sample Report: https://www.blueweaveconsulting.com/women%E2%80%99s-healthcare-market-bwc20103/report-sample

The Prolia drug sub-segment occupies the largest market share in the global women’s healthcare market

Based on drugs, the global women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Zometa, Reclast/Aclasta, Minastrin 24 Fe, FORTEO, Premarin, ACTONEL, and others. Prolia accounted for the largest market share in the global women’s healthcare market in 2020 and is further projected to record a strong CAGR during the forecast period (2021-2027). The drug acts as an effective medicine for curing osteoporosis in women. Since women are more prone to confront bone and calcium-related issues than men, the need for bone-related treatment becomes inevitable making the drug more essential for consumption. As a result, the drug has been driving the growth of the global women’s healthcare market.

The hospitals & clinics segment registered the largest share in the global women’s healthcare market’s end-user segment

Based on end-users, the global women’s healthcare market is segmented into hospitals & clinics, gynecology centers, research institutes, and others. The hospitals & clinics segment accounted for the largest share in the global women’s healthcare market and is expected to register a healthy CAGR during the forecast period.  People prefer visiting hospitals and gynaecology centers owing to the presence of specialized and highly qualified surgeons and physicians. The growing insurance and reimbursement policies driven by the government initiatives in various developed regions have been driving women to opt for treatments in hospitals.

The Global Women’s Healthcare Market: Regional Insights

Based on region, the global women’s healthcare market is divided into North America, Europe, the Asia-Pacific, Latin America, and the Middle East and Africa. In the year 2020, the North American region accounted for the greatest market share in the global women’s healthcare market. According to U.S. census demographics, the region has a growing female population over the age of 35, which indicates a rising demand for female healthcare. This will have a significant impact on the demand for treatment and drugs associated with women's healthcare in the region, as well as the global women's healthcare market.

COVID-19 Impact Analysis

The UN report on the impact of COVID-19 on women discovered that overburdened health facilities, as a result of COVID-19, are diverting resources away from services women require, such as pre- and post-natal healthcare and contraception. When it comes to accessing help, women confront unique challenges. According to the findings of a recent UN Women and UNFPA report, 'Impact of COVID-19 on Gender Equality and Women's Empowerment in East and Southern Africa', the pandemic has had far-reaching and diversified repercussions on women and girls in East and Southern Africa. Additionally, there has been an upsurge in the incidence of neonatal and maternal problems in COVID-19 positive pregnant mothers. It has resulted in an increased rate of miscarriage, preterm birth, pre-eclampsia, cesarean section, and perinatal death. These fatal complications have created the demand for an effective and accessible women's healthcare market for all of its users worldwide.

Some of the leading players in the global women’s healthcare market are Bayer AG, Allergan, Becton & Dickson, Elly Lilly, Merck & Co, Pfizer Inc., Amgen, Agile Therapeutics Inc., Ferring Pharmaceuticals Mylan N.V., and other prominent players. The prevalence of various women’s healthcare manufacturers around the world has paved the way for rising opportunities among the new entrants in the global women’s healthcare market owing to which the global women’s healthcare is fragmented in nature.

In May 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.

Don’t miss the business opportunity of the Global Women’s Healthcare market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global women’s healthcare market size & forecast. The report promises to provide recent technology trends of the global women’s healthcare market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the global women’s healthcare market.

Contact Us:

BlueWeave Consulting Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com

https://www.linkedin.com/company/blueweaveconsulting/

[peeterdbmr]

Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus. A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level